Oncology practices manage PHI at a level of sensitivity that has real consequences for patients beyond the clinical setting. A cancer diagnosis can affect insurance eligibility, employment, and personal relationships. Patients are acutely aware that this information is sensitive. Practices that handle it without deliberate compliance controls create both legal exposure and patient trust problems.
PHI Risks Specific to Oncology Practices
Infusion scheduling records. The infusion center schedule links patient identity to treatment dates. In a community oncology practice, that schedule is visible to multiple staff members and is often managed in systems that also serve scheduling functions for other departments. Access should be limited to staff with a direct treatment role. A schedule printout left in a common area or emailed in plain text is a Privacy Rule exposure.
Treatment records and chemotherapy orders. Chemotherapy order records are detailed, include specific drug regimens, and reference underlying diagnoses. These records move between oncology nurses, pharmacists, and infusion staff. Each handoff is a PHI transmission point that needs documented handling protocols and, where electronic, Security Rule-compliant controls.
Clinical trial PHI. Many community oncology practices enroll patients in cooperative group trials or sponsored research. PHI generated during a trial is subject to the HIPAA Privacy Rule, and its use for research purposes requires either IRB approval with a waiver of authorization or a HIPAA-compliant individual authorization. Practices must coordinate with the trial sponsor and IRB to determine which mechanism applies before sharing trial PHI.
Genetic information. Tumor genomic profiling and germline genetic testing are increasingly standard in oncology. Genetic information is PHI under 45 CFR 160.103. The HIPAA Privacy Rule, as amended by GINA (the Genetic Information Nondiscrimination Act of 2008) and the HITECH Act, prohibits health plans from using genetic information for underwriting purposes and imposes additional restrictions on its disclosure. For oncology practices, this means results from germline testing (BRCA, Lynch syndrome panels, and similar) warrant role-based access controls tighter than standard clinical records. Results from third-party genomic labs require BAAs and documented access controls.
Tumor registry reporting. Most states require oncology practices and the facilities where cancer cases are diagnosed and treated to report cases to the state cancer registry. These mandatory reports are permitted disclosures under 45 CFR 164.512(b) without individual patient authorization, but the practice must document the legal basis for each report. Some cancer registries also receive data from the National Cancer Institute’s SEER program, which involves additional data use agreements. The registry vendor handling data submission is a business associate and requires a BAA.
Multi-provider coordination. An oncology patient’s care team often includes a medical oncologist, a radiation oncologist, a surgical oncologist, a palliative care specialist, and the patient’s primary care physician. Coordinating records across that group involves multiple disclosure events, each of which must comply with the Privacy Rule’s treatment purpose exception or a valid authorization.
Common Compliance Gaps
Oncology practices most often identify two recurring compliance gaps: no formal BAA with the genomic testing laboratories that provide sequencing results, and training documentation that covers the clinical team but misses front desk and scheduling staff who have significant access to the infusion schedule and patient contact records.
What PHIGuard Provides
PHIGuard provides oncology practice administrators with a compliance management platform that does not require a compliance officer to operate. The platform includes:
- Training tracking per §164.530(b), with timestamps for every staff member
- Incident log with guided breach risk assessment per 45 CFR 164.402
- BAA inventory for genomic labs, infusion pharmacy partners, and trial sponsors
- Compliance task templates for annual risk analysis, policy review, and training cycles
- Immutable audit trail on all compliance records
Pricing is per practice, not per physician or staff member. Essentials at $99/month, Clinic at $249/month, Group at $499/month. See plan details and tier limits before selecting a tier, or visit the HIPAA compliance overview for the regulatory framework that applies to oncology practices.